Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
The Ahmedabad-based drug maker reported net profit of Rs 297 crore in the corresponding period of previous year.
On a quarter-on-quarter (QoQ) basis the net profit rose 49.7%.
Revenue from operations rose 10.4% YoY to Rs 5534 crore in Q4FY24 compared to Rs 5010.6 crore in Q4FY23. On QoQ revenue grew 23%.
The earnings before interest, tax, depreciation and amortisation (EBITDA) increased 30% YoY to Rs 1630.5 crore. The EBITDA margins for Q4FY24 improved 440 basis points YoY to 29.5%.
For the full year FY24, Zydus revenue rose 13.4% YoY to Rs 19,547 crore with a net profit of Rs 3859.5 crore. The full year EBITDA stood at 27.5%.
India sales rose 8% YoY to Rs 2,156 crore in Q4FY24. The formulation business gained 7.1% to Rs 1,380.6 crore, while consumer wellness sales grew 9.6% to Rs 7,75.5 crore. India contributes 40% of overall sales.
US formulation business that constitutes 47% grew 12% YoY to Rs 2523.5 crore. Emerging markets and Europe formulation business rose 12.9% YoY to Rs 496 crore.
The active pharmaceutical ingredient (API) business dropped 24% YoY to 143 crore.
The capital expansion for the quarter was Rs. 212.6 crore, while the research & development (R&D) investments for the quarter stood at Rs. 351.6 crore or 6.4% of revenues.
«We aspire to sustain strong performance in fiscal year 2024-25 with strong revenue growth and
